Paediatrics Search

Paediatrics

Paediatrics

Home News Diseases Conferences Special Reports Multimedia

pityriasis%20(tinea)%20versicolor%20(pediatric)

PITYRIASIS (TINEA) VERSICOLOR (PEDIATRIC)

Pityriasis (tinea) versicolor is a benign, superficial, common fungal infection localized to the stratum corneum.
It occurs most commonly in postpubertal individuals when the sebaceous glands are the most active.
Facial involvement is common in adolescents, but lesions are also found on the upper trunk, neck, arms, dorsum of the hand and pubis.
Patient presents with erythematous, hypo- or hyperpigmented macules or patches that may have a slight scale.
It is caused by the lipophilic yeast Malassezia furfur.

Pityriasis%20(tinea)%20versicolor%20(pediatric) Treatment

Treatment

Pharmacotherapy

Condition chronically recurs in predisposed patients despite adequate initial treatment
Skin discoloration may take several weeks to resolve after complete treatment

Topical Antifungals

Effect: Topical treatments are typically effective in temporarily eradicating the disease

Selenium Sulfide & Imidazoles

These agents are equally effective w/ 60-80% recurrence rate

Oral Antifungals

Oral therapy is indicated in cases of severe or widespread skin involvement, recurrent infections & failure of topical therapy
Oral therapy can be convenient & less time consuming enhancing patient compliance
Effect: Infection recurrence may occur less frequently if treated w/ oral antifungals

Combined Ag/Ab rapid testing boosts case-finding in COVID-19

Elvira Manzano, 29 Jul 2021

A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.

Product Highlight - Zinforo

16 Jun 2021

Ceftaroline fosamil 600 mg powder for infusion

Immunotherapy sparks hope for paediatric ALL

Audrey Abella, 14 Oct 2020

Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.